Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Juda Scott, holds the title of Director at Inmune Bio, Inc..
On 2026-07-02, the insider transacted 14,801 shares.The shares were transacted at a weighted average price of $1.40 per share, resulting in a total market-relevant value of $21K.
Juda Scott (Director) exercised options for $21K of $INMB
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.